Sangamo Therapeutics Reports Business Highlights and Third Quarter 2020 Financial Results

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/12/2026

1. MIRM
2. SPY
3. MSFT
4. META
5. LDOS
6. PLTR
7. KTOS
8. NVDA
9. CSCO
10. QQQ

Go back to Sangamo Therapeutics Reports Business Highlights and Third Quarter 2020 Financial Results

Sangamo Therapeutics (SGMO) Tops Q3 EPS by 23c, Revenues Beat

November 4, 2020 5:16 PM EST

Sangamo Therapeutics (NASDAQ: SGMO) reported Q3 EPS of ($0.01), $0.23 better than the analyst estimate of ($0.24). Revenue for the quarter came in at $57.76 million versus the consensus estimate of $26.55 million.

Business Updates

Earned a $30 million milestone from Pfizer for the dosing of the first patient in the registrational Phase 3 AFFINE study of investigational hemophilia A gene therapy giroctocogene fitelparvovec (SB-525).Pfizer provided updated data from... More